Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 448

1.

Rationally designed turn promoting mutation in the amyloid-β peptide sequence stabilizes oligomers in solution.

Rajadas J, Liu CW, Novick P, Kelley NW, Inayathullah M, Lemieux MC, Pande VS.

PLoS One. 2011;6(7):e21776. doi: 10.1371/journal.pone.0021776. Epub 2011 Jul 22.

2.

The Japanese mutant Aβ (ΔE22-Aβ(1-39)) forms fibrils instantaneously, with low-thioflavin T fluorescence: seeding of wild-type Aβ(1-40) into atypical fibrils by ΔE22-Aβ(1-39).

Cloe AL, Orgel JP, Sachleben JR, Tycko R, Meredith SC.

Biochemistry. 2011 Mar 29;50(12):2026-39. doi: 10.1021/bi1016217. Epub 2011 Feb 24.

3.

Stabilization of neurotoxic Alzheimer amyloid-beta oligomers by protein engineering.

Sandberg A, Luheshi LM, Söllvander S, Pereira de Barros T, Macao B, Knowles TP, Biverstål H, Lendel C, Ekholm-Petterson F, Dubnovitsky A, Lannfelt L, Dobson CM, Härd T.

Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15595-600. doi: 10.1073/pnas.1001740107. Epub 2010 Aug 16.

4.

Antiparallel β-Sheet Structure within the C-Terminal Region of 42-Residue Alzheimer's Amyloid-β Peptides When They Form 150-kDa Oligomers.

Huang D, Zimmerman MI, Martin PK, Nix AJ, Rosenberry TL, Paravastu AK.

J Mol Biol. 2015 Jul 3;427(13):2319-28. doi: 10.1016/j.jmb.2015.04.004. Epub 2015 Apr 16.

5.

Solid-state NMR sequential assignment of Osaka-mutant amyloid-beta (Aβ1-40 E22Δ) fibrils.

Huber M, Ovchinnikova OY, Schütz AK, Glockshuber R, Meier BH, Böckmann A.

Biomol NMR Assign. 2015 Apr;9(1):7-14. doi: 10.1007/s12104-013-9535-x. Epub 2014 Jan 7.

PMID:
24395155
6.

Atomic-resolution three-dimensional structure of amyloid β fibrils bearing the Osaka mutation.

Schütz AK, Vagt T, Huber M, Ovchinnikova OY, Cadalbert R, Wall J, Güntert P, Böckmann A, Glockshuber R, Meier BH.

Angew Chem Int Ed Engl. 2015 Jan 2;54(1):331-5. doi: 10.1002/anie.201408598. Epub 2014 Nov 13.

7.

The Alzheimer's amyloid-β(1-42) peptide forms off-pathway oligomers and fibrils that are distinguished structurally by intermolecular organization.

Tay WM, Huang D, Rosenberry TL, Paravastu AK.

J Mol Biol. 2013 Jul 24;425(14):2494-508. doi: 10.1016/j.jmb.2013.04.003. Epub 2013 Apr 11.

PMID:
23583777
8.

Molecular basis for amyloid-beta polymorphism.

Colletier JP, Laganowsky A, Landau M, Zhao M, Soriaga AB, Goldschmidt L, Flot D, Cascio D, Sawaya MR, Eisenberg D.

Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):16938-43. doi: 10.1073/pnas.1112600108. Epub 2011 Sep 23.

9.

Aβ monomers transiently sample oligomer and fibril-like configurations: ensemble characterization using a combined MD/NMR approach.

Rosenman DJ, Connors CR, Chen W, Wang C, García AE.

J Mol Biol. 2013 Sep 23;425(18):3338-59. doi: 10.1016/j.jmb.2013.06.021. Epub 2013 Jun 25.

10.

Unmodified and pyroglutamylated amyloid β peptides form hypertoxic hetero-oligomers of unique secondary structure.

Goldblatt G, Cilenti L, Matos JO, Lee B, Ciaffone N, Wang QX, Tetard L, Teter K, Tatulian SA.

FEBS J. 2017 May;284(9):1355-1369. doi: 10.1111/febs.14058. Epub 2017 Apr 10.

PMID:
28294556
11.

Alzheimer's disease amyloid β-protein mutations and deletions that define neuronal binding/internalization as early stage nonfibrillar/fibrillar aggregates and late stage fibrils.

Poduslo JF, Howell KG, Olson NC, Ramirez-Alvarado M, Kandimalla KK.

Biochemistry. 2012 May 15;51(19):3993-4003. doi: 10.1021/bi300275g. Epub 2012 May 7.

PMID:
22545812
12.

Seeded growth of beta-amyloid fibrils from Alzheimer's brain-derived fibrils produces a distinct fibril structure.

Paravastu AK, Qahwash I, Leapman RD, Meredith SC, Tycko R.

Proc Natl Acad Sci U S A. 2009 May 5;106(18):7443-8. doi: 10.1073/pnas.0812033106. Epub 2009 Apr 17.

13.

Effects of the Arctic (E22-->G) mutation on amyloid beta-protein folding: discrete molecular dynamics study.

Lam AR, Teplow DB, Stanley HE, Urbanc B.

J Am Chem Soc. 2008 Dec 24;130(51):17413-22. doi: 10.1021/ja804984h. Erratum in: J Am Chem Soc. 2011 Mar 2;133(8):2789.

14.

Solid-state NMR sequential assignment of an Amyloid-β(1-42) fibril polymorph.

Ravotti F, Wälti MA, Güntert P, Riek R, Böckmann A, Meier BH.

Biomol NMR Assign. 2016 Oct;10(2):269-76. doi: 10.1007/s12104-016-9682-y. Epub 2016 May 10.

PMID:
27165577
15.

The ongoing search for small molecules to study metal-associated amyloid-β species in Alzheimer's disease.

Savelieff MG, DeToma AS, Derrick JS, Lim MH.

Acc Chem Res. 2014 Aug 19;47(8):2475-82. doi: 10.1021/ar500152x. Epub 2014 Jul 31.

PMID:
25080056
16.

Expression and purification of 15N- and 13C-isotope labeled 40-residue human Alzheimer's β-amyloid peptide for NMR-based structural analysis.

Long F, Cho W, Ishii Y.

Protein Expr Purif. 2011 Sep;79(1):16-24. doi: 10.1016/j.pep.2011.05.012. Epub 2011 May 27.

17.

Interaction between amyloid beta peptide and an aggregation blocker peptide mimicking islet amyloid polypeptide.

Rezaei-Ghaleh N, Andreetto E, Yan LM, Kapurniotu A, Zweckstetter M.

PLoS One. 2011;6(5):e20289. doi: 10.1371/journal.pone.0020289. Epub 2011 May 25.

18.

Polymorphic structures of Alzheimer's β-amyloid globulomers.

Yu X, Zheng J.

PLoS One. 2011;6(6):e20575. doi: 10.1371/journal.pone.0020575. Epub 2011 Jun 7.

19.

Molecular dynamics simulations to investigate the structural stability and aggregation behavior of the GGVVIA oligomers derived from amyloid beta peptide.

Chang LK, Zhao JH, Liu HL, Liu KT, Chen JT, Tsai WB, Ho Y.

J Biomol Struct Dyn. 2009 Jun;26(6):731-40.

PMID:
19385701
20.

Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers.

Robert R, Dolezal O, Waddington L, Hattarki MK, Cappai R, Masters CL, Hudson PJ, Wark KL.

Protein Eng Des Sel. 2009 Mar;22(3):199-208. doi: 10.1093/protein/gzn052. Epub 2008 Oct 16.

PMID:
18927231

Supplemental Content

Support Center